Charles Rowland Elected to BIND Therapeutics Board of Directors

Charles Rowland Elected to BIND Therapeutics Board of Directors

May 28, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced that at BIND’s annual meeting of stockholders held today the company’s stockholders elected Mr. Charles A. Rowland, Jr., CPA, most recently the Vice President and Chief Financial Officer of ViroPharma Incorporated, to its Board of Directors.

Joule Names Tom Einar Jensen Head of Corporate Development

Joule Names Tom Einar Jensen Head of Corporate Development

May 21, 2014

Bedford, MA – May 21, 2014 – Joule today announced the appointment of Tom Einar Jensen as Executive Vice President, Head of Corporate Development, providing leadership in the areas of investment, business development, strategy, communication and commercialization. 

Moderna Forms Technology Advisory Board to Provide Expertise for the Company's GMP Manufacturing Strategy

Moderna Forms Technology Advisory Board to Provide Expertise for the Company's GMP Manufacturing Strategy

May 21, 2014

CAMBRIDGE, Mass., May 21, 2014 /PRNewswire/ -- Moderna Therapeutics, the pioneer in developing messenger RNA (mRNA) Therapeutics™, a revolutionary treatment modality to enable the in vivo production of therapeutic proteins, announced today the formation of a Technology Advisory Board.

Acceleron Pharma Reports First Quarter 2014 Financial Results

Acceleron Pharma Reports First Quarter 2014 Financial Results

May 15, 2014

Positive clinical data from all three phase 2 programs to be presented at ASCO and EHA meetings

Follow-on offering solidifies financial position and provides funding into second half of 2017 

Joule Achieves ASTM Compliance for Sustainable Diesel, Jet Fuel

Joule Achieves ASTM Compliance for Sustainable Diesel, Jet Fuel

May 15, 2014

BIO World Congress on Industrial Biotechnology – Philadelphia, PA – May 15, 2014 – Marking another step towards commercial readiness of CO2-neutral fuels,  Joule today announced that its Sunflow®-D and Sunflow®-J products meet the standards of the American Society for Testing and Materials (ASTM) for diesel and jet fuel, respectively.

Eleven Biotherapeutics Reports Fiscal First Quarter 2014 Financial Results

Eleven Biotherapeutics Reports Fiscal First Quarter 2014 Financial Results

May 15, 2014

- Enrollment Complete in EBI-005 Phase 2 Allergic Conjunctivitis Study -

BG Medicine Reports First Quarter 2014 Financial Results

BG Medicine Reports First Quarter 2014 Financial Results

May 14, 2014

 BG Medicine Reports First Quarter 2014 Financial Results

Net Loss Reduced by 60% and Operating Cash Burn Cut by 44% From First Quarter 2013

Continued Progress Made Toward Delivering on Critical Catalysts for Growth

WALTHAM, Mass., May 14, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3(R) Test, today reported financial results for the first quarter ended March 31, 2014.

Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer

Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer

May 14, 2014

Appointment Reflects the Strength of Agios’ Clinical Development Pipeline

Concert Pharmaceuticals Reports First Quarter 2014 Financial Results

Concert Pharmaceuticals Reports First Quarter 2014 Financial Results

May 14, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2014.

Avedro Welcomes Robert J. Palmisano to its Board of Directors

Avedro Welcomes Robert J. Palmisano to its Board of Directors

May 14, 2014

Seasoned Veteran in Value Creation for Ophthalmic Medical Device Companies